Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Purpose: This study aimed to determine the risk factors for palbociclib-induced grade 4 or grade 3 neutropenia (NP) requiring dose reduction or delayed treatment in patients with HR+/HER2−metastatic breast cancer in the first 3 cycles (early grade 3/4 NP) and whether the early developing grade 3/4 N...

Full description

Bibliographic Details
Main Authors: Yeonhong Lee, Dayae Lee, Inyoung Seo, Heejung Chae, Sung Hoon Sim, Keun Seok Lee, Hye Sun Gwak
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Cancers
Subjects:
metastatic breast cancer
palbociclib
neutropenia
CDK4/6 inhibitor
Online Access:https://www.mdpi.com/2072-6694/15/10/2810

Internet

https://www.mdpi.com/2072-6694/15/10/2810

Similar Items